Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $197.41M
• Dividend Yield: N/A
• Average Volume (3M): 199.30K
• Price to Earnings (P/E): 7.4
• Beta (1Y): 1.59
• Revenue Growth: -66.80%
• EPS Growth: -157.68%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 38,037,080
• 10 Day Avg. Volume: 306,319
• 30 Day Avg. Volume: 199,298
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.11
• Enterprise Value/Revenue: -0.12
• Enterprise Value/Gross Profit: -0.13
• Enterprise Value/Ebitda: -3.55
• 1Y Price Target: $18.50
• Price Target Upside: 256.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 60 Neutral
• Price Target: $6.50 ▲(25.24% Upside)

The overall stock score for Entrada Therapeutics Inc. is primarily influenced by its strong financial performance and attractive valuation. However, bearish technical indicators and recent declines in revenue and net income temper the outlook. The strategic board appointment is a positive development, but the company's ability to manage cash flows and sustain growth remains critical.

Positive Factors

Clinical Development

Multiple candidates advancing in clinical development positions Entrada favorably to become a one-stop shop for DMD patients needing exon-skipping therapies.

Financial Stability

Entrada ended with $354M in cash, expected to be sufficient to fund operations into 2Q27.

Regulatory Progress

Key regulatory clearances obtained, clearing path for multiple global clinical development programs to advance.

Negative Factors

Clinical Risks

Risks include failure to generate favorable mid-stage clinical data and inability to advance lead candidates into pivotal trials in a timely manner.

Financial Performance

Entrada Therapeutics recorded top-line revenue of ~$2M, missing the forecast of $8M.

Partnership and Dilution Risks

Risks include partnership risks and long-term dilution risk.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics Inc (TRDA) is a biotechnology company focused on developing intracellular biologics to treat devastating diseases. The company operates in the biotechnology sector, specializing in the development of novel therapeutics that can target intracellular disease drivers, addressing challenges associated with delivering biologics into cells. Entrada's core products include its proprietary Endosomal Escape Vehicle (EEV) technology, which is designed to enable the delivery of various therapeutic modalities, including nucleic acids, peptides, and proteins, directly into the cell cytosol.

How the Company Makes Money

Entrada Therapeutics generates revenue through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve licensing their proprietary EEV technology for the development of therapies targeting specific diseases, leading to potential milestone payments and royalties based on the success of the partnered products. Additionally, Entrada may earn revenue from government grants or research funding to support its innovative therapeutic projects. As the company advances its own pipeline of investigational drugs, future revenue could also come from the commercialization of its proprietary therapeutics, contingent upon successful clinical trials and regulatory approval.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Entrada Therapeutics Inc. has shown impressive revenue growth and improving profitability over the past years. However, recent declines in revenue and net income, coupled with negative cash flow, highlight the need for strategic management to sustain growth and financial stability.

Income Statement

Entrada Therapeutics Inc. has demonstrated significant revenue growth over recent years, with a notable increase in total revenue from $0 in 2021 to $210.78 million in 2024. The company achieved a positive net income of $65.63 million in 2024, indicating improving profitability. However, the TTM data shows a decline in revenue to $172.22 million and net income to $24.78 million, suggesting recent challenges. Gross profit margins have been strong, and the EBIT and EBITDA margins indicate operational efficiency improvements. Despite these, the recent dip in revenue and earnings raises concerns about sustaining growth momentum.

Balance Sheet

The balance sheet reveals a solid equity position with a stockholders' equity of $417.26 million in the latest TTM. The debt-to-equity ratio remains low, indicating prudent financial leverage. The company's total assets have grown significantly, and cash reserves are robust, reflecting strong liquidity. However, the stability of equity amidst fluctuating liabilities warrants attention. Overall, the balance sheet showcases financial stability, though vigilance is needed to maintain a low leverage profile.

Cash Flow

Cash flow analysis shows a volatile operating cash flow, with the latest TTM indicating a negative figure of $-54.55 million. Free cash flow has also been negative, reflecting high capital expenditures relative to cash generated from operations. The substantial financing cash flow suggests reliance on external funding to support operations. While capital investments are necessary for growth, the persistent cash outflows pose a risk if not offset by future revenue increases.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	210.78M	129.01M	0.00	0.00	0.00
Gross Profit	207.01M	29.13M	-1.90M	-1.12M	-326.00K
EBITDA	47.01M	-321.00K	-95.35M	-50.01M	-26.34M
Net Income	65.63M	-6.68M	-87.46M	-50.07M	-26.38M
Balance Sheet
Total Assets	526.32M	469.19M	252.06M	305.83M	43.53M
Cash, Cash Equivalents and Short-Term Investments	420.00M	351.97M	45.16M	291.06M	39.05M
Total Debt	59.21M	68.23M	25.94M	0.00	0.00
Total Liabilities	97.64M	226.83M	39.50M	7.12M	85.02M
Stockholders Equity	428.68M	242.36M	212.55M	298.72M	-41.49M
Cash Flow
Free Cash Flow	-44.72M	134.19M	-96.67M	-55.44M	-27.89M
Operating Cash Flow	-41.56M	139.80M	-93.79M	-50.86M	-25.57M
Investing Cash Flow	-27.80M	-138.40M	-148.65M	-4.58M	-2.32M
Financing Cash Flow	102.96M	21.04M	479.00K	307.46M	50.09M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Negative. The current price of 5.19 is below the 20-day moving average (MA) of 6.15, below the 50-day MA of 6.92, and below the 200-day MA of 11.75, indicating a bearish trend. The MACD of -0.40 indicates Positive momentum. The RSI at 30.53 is Neutral, neither overbought nor oversold. The STOCH value of 27.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	74 Outperform	$568.61M	5.86	376.09%	―	105.62%	―
TRDA	60 Neutral	$197.41M	7.36	-18.12%	―	-66.80%	-157.68%
ZBIO	58 Neutral	$612.03M	―	-115.47%	―	―	―
AMLX	57 Neutral	$681.24M	―	-87.42%	―	-100.32%	-197.69%
BNTC	47 Neutral	$309.76M	―	-48.57%	―	-100.00%	83.98%
Sector *	47 Neutral	C$190.13M	-2.29	-23.77%	3.17%	17.53%	1.84%
ALLO	43 Neutral	$227.48M	―	-59.60%	―	-100.00%	31.43%

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics Holds Virtual Annual Stockholders Meeting

On June 11, 2025, Entrada Therapeutics, Inc. held its Annual Meeting of Stockholders virtually, where a quorum was established with 30,259,526 shares represented. During the meeting, stockholders elected three Class I directors to the Board and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TRDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.

Entrada Therapeutics Appoints New Board Member

On May 30, 2025, Entrada Therapeutics expanded its Board of Directors from six to seven members, appointing Maha Radhakrishnan, M.D., as a Class III director and a member of the Audit Committee, effective June 1, 2025. Dr. Radhakrishnan brings extensive experience in global drug development, which is expected to support Entrada’s clinical momentum, particularly in advancing its Duchenne muscular dystrophy programs. Her appointment is seen as a strategic move to enhance the company’s capability in delivering innovative therapies for serious illnesses.

The most recent analyst rating on (TRDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.